- Home
- SENEB vs XNCR Comparison
SENEB vs XNCR Comparison
Compare SENEB & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | XNCR |
|---|---|---|
| Founded | 1949 | 1997 |
| Country | United States | United States |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.5M | 881.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | SENEB | XNCR |
|---|---|---|
| Price | $139.34 | $12.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.89 |
| AVG Volume (30 Days) | 277.0 | ★ 706.2K |
| Earning Date | 02-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.88 |
| P/E Ratio | $12.93 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $86.92 | $6.92 |
| 52 Week High | $139.31 | $18.69 |
Technical Indicators
Market Signals| Indicator | SENEB | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 72.91 | 51.38 |
| Support Level | $108.68 | $10.92 |
| Resistance Level | N/A | $12.87 |
| Average True Range (ATR) | 0.18 | 0.70 |
| MACD | 1.69 | 0.06 |
| Stochastic Oscillator | 100.00 | 66.53 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.